|Market Size in 2022||Market Forecast in 2030||CAGR (in %)||Base Year|
|USD 8.91 Billion||USD 14.74 Billion||6.51%||2022|
Methenamine Hippurate Tablets Market
The global methenamine hippurate tablets market size was worth around USD 8.91 Billion in 2022 and is predicted to grow to around USD 14.74 Billion by 2030 with a compound annual growth rate (CAGR) of roughly 6.51% between 2023 and 2030. The report analyzes the global methenamine hippurate tablets market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the methenamine hippurate tablets industry.
Methenamine hippurate tablets are medicines that are used for the treatment or prevention of urinary tract infections (UTIs) caused by bacteria. The medication is generally available in tablet form and methenamine hippurate acts as an important component of the medicine which breaks down in the urine and leads to the release of formaldehyde and hippuric acid. Both of these sub-components exhibit antimicrobial properties. The industry refers to the production and sale of these medicines. It includes stakeholders like suppliers, manufacturers, and distributors. The healthcare professionals that are responsible for prescribing tablets are equally critical to the industry. With the growing rate of UTI infections, the demand for tablets is expected to rise. However, the industry also faces growth restrictions and challenges.
Growing prevalence of UTIs to propel market growth
The global methenamine hippurate tablets market is projected to grow owing to the increasing prevalence of UTIs across the globe. Urinary tract infections are extremely common health concerns that affect millions of people globally. UTIs are mainly caused by bacteria, which in most cases is Escherichia coli (E. coli). It enters the urethra and travels up to the bladder of the patient. In some cases, it can also reach the kidney. The bacteria is known to cause infection in different parts of the urinary tract like the bladder, urethra, and kidneys. As studies have indicated, females are more prone to contracting the condition due to their anatomy which consists of a shorter urethra making it easier for the bacteria to enter the bladder. Furthermore, sexual activity is known to be a leading cause of UTIs, especially in the female population.
Growing evolution of the bacteria itself to restrict market expansion
One of the key aspects that are likely to impede global methenamine hippurate tablets market growth is the emergence of antibiotic-resistant bacteria. Due to misuse or overuse of the medicine, the associated bacteria have managed to evolve thus becoming resistant to the effects of the medication. This is a major area of concern in the medical community since this evolution restricts the effectiveness of tablets. Furthermore, the lack of awareness amongst the population about UTIs and precautionary or preventative measures is another significant cause of reduced growth in the industry.
Growing demand for preventive care to provide growth opportunities
As the world is gaining more knowledge on the importance and benefits of preventive care, especially after Covid-19, the global industry may witness higher revenue during the forecast period. Preventive care is essential since it can assist individuals to maintain a healthy lifestyle and prevent the onset of any serious condition. By undertaking the necessary steps to maintain good health, people can avoid spending on costly medical processes and treatments later on in life. For example, one of the ways of preventing UTI is drinking lots of water or taking medications like methenamine hippurate tablets under a doctor’s guidance.
Limited availability in developing nations to challenge market growth
The tablets may not be readily available in developing nations or regions that are currently suffering from various social-political-economical factors. Issues like limited healthcare infrastructure, the absence of specialists, and other regulatory issues may pose a challenge to the global methenamine hippurate tablets industry size. Furthermore, the increasing adoption of alternative techniques to prevent UTIs or treat them is another significant factor to be considered by analyzing challenging situations in the industry.
The global methenamine hippurate tablets market is segmented based on application, type, distribution channel, end-users, and region.
Based on application, the global market segments are healthcare-associated UTIs and uncomplicated UTIs. In 2022, the industry registered the highest growth in the uncomplicated UTIs segment. This is mainly because this type of infection is generally caused by bacteria which can be treated with methenamine hippurate tablets since the bacteria is susceptible to the medicines and can be treated with it alone. However, healthcare-associated UTIs are generally caused by more serious conditions and may be the result of antibiotic-resistant bacteria. In such cases, medical professionals may prescribe the tablet in combination with other antibiotics. In the United States, UTIs are estimated to be responsible for over 8.1 million medical visits every year.
Based on type, the global market divisions are 6 tablets/ bottle and 20 tablets/bottle
Based on distribution channel, the methenamine hippurate tablets industry divisions are online pharmacy, hospital pharmacy, and retail pharmacy. The industry registered the highest CAGR in the hospital pharmacy segment in 2022 since they are most often considered to be one of the largest distribution channels for pharmaceuticals. The high segmental growth is due to large patient populations that regularly visit hospitals for a steady medicine supply. Additionally, they also tend to receive numerous bulk orders. Another crucial segment for the industry expansion is retail pharmacies. They are independent pharmacies or chain drugstores that supply the medicine. Online pharmacies may face regulatory challenges and safety concerns, which could limit their growth and adoption. Uncomplicated UTIs can be treated in 3 to 7 days.
Based on end-users, the global market divisions are homecare, hospitals, specialty clinics, and others.
|Report Attributes||Report Details|
|Report Name||Methenamine Hippurate Tablets Market Research Report|
|Market Size in 2022||USD 8.91 Billion|
|Market Forecast in 2030||USD 14.74 Billion|
|Growth Rate||CAGR of 6.51%|
|Number of Pages||214|
|Key Companies Covered||Almirall, S.A., Mylan N.V., Merck & Co., Inc., Cadila Healthcare Ltd., Pfizer Inc., Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., West-Ward Pharmaceuticals Corp., Abbott Laboratories, Glenmark Pharmaceuticals Ltd., Bausch Health Companies Inc., Procter & Gamble Co., Jubilant Life Sciences Ltd., Lupin Pharmaceuticals, Inc., Cipla Ltd., Amneal Pharmaceuticals LLC., Allergan plc., Novartis AG., and Sanofi S.A.|
|Segments Covered||By Application, By Type, By Distribution Channel, By End-Users, And By Region|
|Regions Covered||North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA)|
|Historical Year||2017 to 2021|
|Forecast Year||2023 - 2030|
|Customization Scope||Avail customized purchase options to meet your exact research needs. Request For Customization|
North America to lead with the highest CAGR
The global methenamine hippurate tablets market is expected to register the highest growth in North America owing to the growing prevalence of urinary tract infections. Furthermore, the regional growth is strengthened due to a higher awareness rate amongst the population about different preventive and treatment options available for treating the condition. The robust medical infrastructure of the US and Canada is essential to the revenue in North America. In addition to this, the regions are witnessing growing investment toward exhaustive research on understanding methenamine hippurate in detail and its further application. High disposable income, growing demand for preventive care, and increasing healthcare expenditure are other significant factors of regional growth.
The global methenamine hippurate tablets market is home to players like:
By Distribution Channel
Methenamine hippurate tablets are medicines that are used for the treatment or prevention of urinary tract infections (UTIs) caused by bacteria.
The global methenamine hippurate tablets market is projected to grow owing to the increasing prevalence of UTIs across the globe.
According to study, the global methenamine hippurate tablets market size was worth around USD 8.91 billion in 2022 and is predicted to grow to around USD 14.74 billion by 2030.
The CAGR value of methenamine hippurate tablets market is expected to be around 6.51% during 2023-2030.
The global methenamine hippurate tablets market is expected to register the highest growth in North America owing to the growing prevalence of urinary tract infections.
The global methenamine hippurate tablets market is home to players like Almirall, S.A., Mylan N.V., Merck & Co., Inc., Cadila Healthcare Ltd., Pfizer Inc., Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., West-Ward Pharmaceuticals Corp., Abbott Laboratories, Glenmark Pharmaceuticals Ltd., Bausch Health Companies Inc., Procter & Gamble Co., Jubilant Life Sciences Ltd., Lupin Pharmaceuticals, Inc., Cipla Ltd., Amneal Pharmaceuticals LLC., Allergan plc., Novartis AG., and Sanofi S.A.